Emergent BioSolutions Keynotes BARDA Industry Day

--(BUSINESS WIRE)-- The threat of biological agents such as anthrax is real. Contracting for countermeasures, the U.S. government works with industry in its preparedness efforts to protect the population. Following opening remarks by Dr. Robin Robinson, BARDA Director, learn about navigating the contracting process and working with the U.S. government in identifying and fulfilling medical countermeasure development and procurement requirements.

     

Who:

Barbara Solow, Ph.D.

VP External Development

Emergent BioSolutions

 

What:

Plenary Session: Working with the U.S. Government

 

When:

June 7, 2011, 8:30 – 10:00 am Pacific

 

Where:

Meeting Room 16 A & B

San Diego Convention Center

111 West Harbor Drive

San Diego, CA 92101

 

About Emergent BioSolutions Inc.

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology, and autoimmune disorders. Additional information about the company may be found at www.emergentbiosolutions.com.



CONTACT:

Emergent BioSolutions
Tracey Schmitt, 301-795-1800
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Defense  Other Defense

MEDIA:

Logo
 Logo

Suggested Articles

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.

Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.